Evidence map›Paper›PMID 31330859›Full record

ReviewCancers2019

Spatiotemporal pH Heterogeneity as a Promoter of Cancer Progression and Therapeutic Resistance.

David E Korenchan, Robert R Flavell

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Anoikis: To Die or Not to Die?International journal of molecular sciences · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David E KorenchanDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143, USA.ORCID 0000-0001-6152-5896
Robert R FlavellDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143, USA. Robert.Flavell@ucsf.edu.
University of California, San Francisco · US

Funding

Application of hyperpolarized 13C interstitial pH imaging to risk stratification in prostate cancerR21EB026012 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FLAVELL, ROBERT RICHARD · 2018 to 2020
$503k
NIBIB NIH HHS R21 EB026012NIH HHS R21-EB026012Prostate Cancer Foundation David Blitzer Young Investigator AwardUniversity of California Cancer Research Committee CRN-19-581541University of California, San Francisco Research Allocation Program Pilot AwardU.S. Department of Defense PC150932
6 · The paper itself

Abstract

Dysregulation of pH in solid tumors is a hallmark of cancer. In recent years, the role of altered pH heterogeneity in space, between benign and aggressive tissues, between individual cancer cells, and between subcellular compartments, has been steadily elucidated. Changes in temporal pH-related processes on both fast and slow time scales, including altered kinetics of bicarbonate-CO

Indexed as

acidosiscarbonic anhydrasehyperpolarized 13C MRIinterstitial pHlactic acidmagnetic resonance imagingpositron emission tomographytumor heterogeneitytumor microenvironment

Identifiers

PMID31330859
PMCPMC6678451
OpenAlexW2964104202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.